Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stem Cells Lenses for Chronic Ocular GVHD
NCT06952114Phase 1Not yet recruiting
- Sponsor
- Guangdong ProCapZoom Biosciences Co., Ltd.
- Start
- May 2025
- Primary completion
- Dec 2025
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of human umbilical cord mesenchymal stem cells in chronic ocular graft-versus-host disease (oGVHD), sponsored by Guangdong ProCapZoom Biosciences Co., Ltd. Primary endpoint: Adverse events. Planned start May 2025; status: not yet recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
chronic ocular graft-versus-host disease (oGVHD)
Beyond the preview
Go deeper on NCT06952114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06952114.